Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une comparaison randomisée des soins personnalisés basés sur le stade de la maladie cardiaque par rapport aux soins habituels pour la prévention des événements (TRANSFORM)

18 novembre 2026 mis à jour par: Cleerly, Inc.

Une comparaison randomisée des soins personnalisés basés sur le stade de la maladie coronarienne par rapport aux soins habituels pour la prévention primaire des événements cardiovasculaires

TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

Cardiovascular disease (CVD) persists as the leading cause of morbidity and mortality worldwide at high societal cost. The current primary CVD prevention strategy relies upon risk stratification using population health markers such as age, sex, diabetes, hypertension, dyslipidemia and tobacco use, with preventive therapy intensified in higher risk strata. Since these risk factors are indirect surrogate markers of the underlying disease, atherosclerosis, this strategy leads to treatment of individuals with risk factors who do not have atherosclerosis and failure to treat those with significant atherosclerosis who lack risk factors. The current strategy also cannot determine which individuals are inadequately treated despite effective risk factor management (residual risk). With the current approach, the CV death rate is trending upward in the US despite evidence that screening asymptomatic patients reduces CV events and the widespread availability of effective preventive therapies.

This randomized, controlled, pragmatic trial is designed to address the unmet need for better strategies to identify asymptomatic individuals at increased risk for CV events due to atherosclerosis and to personalize their treatment based on CV risk estimates using coronary artery disease (CAD) visualization and quantification.

This study enrolls patients without known symptoms of ASCVD but who are at increased risk for ASCVD due to their age and having diabetes, prediabetes or metabolic syndrome and tests the hypothesis that a CAD Staging System-based care strategy reduces CV events compared with risk factor-based care. The Cleerly CAD Staging System incorporates imaging-based evaluation for coronary atherosclerosis, algorithm-supported pharmacotherapy and personalized education about their CAD.

Type d'étude

Interventionnel

Inscription (Estimé)

7500

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Arizona
      • Chandler, Arizona, États-Unis, 85224
        • Recrutement
        • Chandler Clinical Trials
        • Contact:
          • Muhammad Salim, MD
      • Scottsdale, Arizona, États-Unis, 85260
        • Recrutement
        • Scottsdale Clinical Trials
        • Contact:
          • Todd Dreitzler, MD
      • Sun City, Arizona, États-Unis, 85381
        • Recrutement
        • Sun City Research
        • Contact:
          • Juan Rodriguez, MD
      • Tucson, Arizona, États-Unis, 85704
        • Recrutement
        • Noble Clinical Research
        • Contact:
          • Roxana Rodriguez, MD
    • California
      • Beverly Hills, California, États-Unis, 90210
        • Recrutement
        • Cardiovascular Research Foundation of Southern California
        • Contact:
          • Ronald P. Karlsberg, MD
      • Beverly Hills, California, États-Unis, 90211
        • Recrutement
        • Amicis Research: Beverly Hills
        • Contact:
          • Michael Levine, MD
      • Canoga Park, California, États-Unis, 91303
        • Recrutement
        • Valiance Clinical Research - Canoga Park
        • Contact:
          • Rami Shaarawy
      • Chula Vista, California, États-Unis, 91911
        • Recrutement
        • Cardiovascular Institute of San Diego
        • Contact:
          • Milind D. Parikh, MD
      • Granada Hills, California, États-Unis, 91324
        • Recrutement
        • Amicis Research: Granada Hills
        • Contact:
          • Pascal Dabel, MD
      • Huntington Park, California, États-Unis, 90255
        • Recrutement
        • Valiance Clinical Research: Huntington Park
        • Contact:
          • Philip Kim, MD
      • Indian Wells, California, États-Unis, 92210
        • Recrutement
        • HALO Diagnostics
        • Contact:
          • John F. Feller, MD
      • La Jolla, California, États-Unis, 92037
        • Recrutement
        • Scripps Health
        • Contact:
          • Elizabeth Epstein, MD
      • Lancaster, California, États-Unis, 93534
        • Recrutement
        • Chemidox Clinical Trials
        • Contact:
          • Pamela Dewar-DeSilva, MD
      • Loma Linda, California, États-Unis, 92354
        • Recrutement
        • Loma Linda University Health
        • Contact:
          • Purvi Parwani, MD
      • Long Beach, California, États-Unis, 90805
        • Recrutement
        • Long Beach Research Institute
        • Contact:
          • Ashley Duzik, MD
      • Monterey Park, California, États-Unis, 91754
        • Recrutement
        • Ace Research Institute - Monterey Park
        • Contact:
          • Yu-Hsiang Sam Lee, MD
      • Newhall, California, États-Unis, 91321
        • Recrutement
        • Amicis Research: Newhall
        • Contact:
          • Thuong Vo, MD
      • Northridge, California, États-Unis, 91324
        • Recrutement
        • Ace Research Institute: Northridge
        • Contact:
          • Richard Park, MD
      • Northridge, California, États-Unis, 91324
        • Recrutement
        • Amicis Research: Northridge
        • Contact:
          • Nana Barseghian, MD
      • Northridge, California, États-Unis, 91325
        • Recrutement
        • Ace Research Institute: Northridge #2
        • Contact:
          • William Y. Josephson, MD
      • Northridge, California, États-Unis, 91325
        • Actif, ne recrute pas
        • Northridge Clinical Trials
      • Orange, California, États-Unis, 92868
        • Recrutement
        • University of California- Irvine
        • Contact:
          • Ailin Barseghian El-Farra, MD
      • Palo Alto, California, États-Unis, 94304
        • Recrutement
        • Stanford Health Care
        • Contact:
          • Sandra Tsai, MD
      • Palo Alto, California, États-Unis, 94304
        • Recrutement
        • VA Palo Alto
        • Contact:
          • Shriram Nallamshetty, MD
      • San Fernando, California, États-Unis, 91306
        • Recrutement
        • Amicis Research: San Fernando
        • Contact:
          • Farid Yasharpour, MD
      • Tarzana, California, États-Unis, 91356
        • Recrutement
        • Valiance Clinical Research - Tarzana
        • Contact:
          • Harpreet Singh, MD
      • Torrance, California, États-Unis, 90502
        • Recrutement
        • Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center
        • Contact:
          • Suvasini Lakshmanan, MD
      • Valencia, California, États-Unis, 91355
        • Recrutement
        • Amicis Research: Valencia
        • Contact:
          • Dennis Lewis, MD
      • Valley Village, California, États-Unis, 91607
        • Recrutement
        • Concierge Clinical Trials
        • Contact:
          • Neal R. Cutler, MD
    • Colorado
      • Aurora, Colorado, États-Unis, 80045
        • Recrutement
        • University of Colorado
        • Contact:
          • Steve Simon
        • Chercheur principal:
          • Steve Simon, MD
      • Denver, Colorado, États-Unis, 80218
        • Recrutement
        • St. Josephs (Intermountain Healthcare)
        • Contact:
          • Christopher Angus, MD
    • Florida
      • Boca Raton, Florida, États-Unis, 33434
        • Recrutement
        • Flourish Medical Research
        • Contact:
          • Michael Hafran, MD
      • Cross City, Florida, États-Unis, 32628
        • Recrutement
        • Apex Research
        • Contact:
          • Tamir Salmani, MD
      • Hialeah, Florida, États-Unis, 33012
        • Recrutement
        • Evolution Research Center
        • Contact:
          • Riquel Gonzalez, MD
      • Jacksonville, Florida, États-Unis, 32209
        • Recrutement
        • UF Health Jacksonville
        • Contact:
          • Luis Ortega Paz, MD
      • Miami, Florida, États-Unis, 33137
        • Recrutement
        • BioPhase Research
        • Contact:
          • Julie Cadet-Plassman, MD
      • Miami, Florida, États-Unis, 33135
        • Recrutement
        • Fiel Wellness Clinical Research LLC
        • Contact:
          • Osvaldo Caroma, MD
      • Miami, Florida, États-Unis, 33155
        • Recrutement
        • United Clinical Research
        • Contact:
          • Teresa B. Alfonso, MD
        • Contact:
          • Alfonso
      • Miami, Florida, États-Unis, 33173
        • Recrutement
        • Atlantis Clinical Research, LLC
        • Contact:
          • Leyvi Alvarado Miranda, MD
      • Miami, Florida, États-Unis, 33183
        • Recrutement
        • Farma Medical Inc.
        • Contact:
          • Ingrid Fernandez-Milian, MD
      • Miami, Florida, États-Unis, 33173
        • Recrutement
        • Baptist Health Miami Cardiac and Vascular Institute
        • Contact:
          • Jonathan Fialkow, MD
      • Miami, Florida, États-Unis, 33186
        • Recrutement
        • New Access Research and Medical Center
        • Contact:
          • Sander Fernandez, MD
      • Miami Beach, Florida, États-Unis, 33140
        • Recrutement
        • Quantum Clinical Trials
        • Contact:
          • Christopher A. Fayeghi, MD
      • Pensacola, Florida, États-Unis, 32504
        • Recrutement
        • Ascension Sacred Heart
        • Contact:
          • Rohit Amin, MD
      • Pompano Beach, Florida, États-Unis, 33060
        • Recrutement
        • Clinical Research Center of Florida
        • Contact:
          • Howard S. Koch, MD
      • Tampa, Florida, États-Unis, 33620
        • Recrutement
        • University of South Florida
        • Contact:
          • Shone Almeida, MD
    • Georgia
      • Augusta, Georgia, États-Unis, 30907
        • Recrutement
        • Aiyan Diabetes Center
        • Contact:
          • Anthony D. Turner, MD
      • Dunwoody, Georgia, États-Unis, 30338
        • Recrutement
        • Emory University
        • Contact:
          • Ambar Kulshreshtha, MD
      • Fayetteville, Georgia, États-Unis, 30214
        • Recrutement
        • Privia Medical Group Georgia LLC -Fayetteville (Javara)
        • Contact:
          • Charlotte Grayson Mathis, MD
      • Lithia Springs, Georgia, États-Unis, 30122
        • Recrutement
        • Randomize Now- Atlanta West
        • Contact:
          • Millard Collier Jr., MD
      • Macon, Georgia, États-Unis, 31210
        • Recrutement
        • Randomize Now-Burton Medical
        • Contact:
          • Frederick Burton, MD
      • Norcross, Georgia, États-Unis, 30092
        • Recrutement
        • Evergreen Clinical Trials
        • Contact:
          • Dmitriy Pelishev, MD
      • Powder Springs, Georgia, États-Unis, 30127
        • Recrutement
        • Peachtree Clinical Solutions - Noir Research Collective
        • Contact:
          • Karan Raghavan, MD
      • Riverdale, Georgia, États-Unis, 30296
        • Recrutement
        • Randomize Now, LLC - Noir Research Collective
        • Contact:
          • Claire K. Willie, MD
      • Savannah, Georgia, États-Unis, 31406
        • Recrutement
        • Privia Medical Group Georgia, LLC (Javara Inc.)
        • Contact:
          • Thomas G. Moriarity, MD
      • Thomasville, Georgia, États-Unis, 31792
        • Recrutement
        • Privia Medical Group Georgia - Thomasville (Javara)
        • Contact:
          • William L. Cooper, MD
    • Idaho
      • Meridian, Idaho, États-Unis, 83642
        • Recrutement
        • Care Institute- High Desert
        • Contact:
          • David A. Hinchman, MD
    • Illinois
      • Chicago, Illinois, États-Unis, 60611
        • Recrutement
        • Northwestern University
        • Contact:
          • Paul C. Cremer, MD
      • Glenview, Illinois, États-Unis, 60026
        • Recrutement
        • Northshore University Health System
        • Contact:
          • Amit K. Pursnani, MD
    • Indiana
      • Indianapolis, Indiana, États-Unis, 46237
        • Recrutement
        • Franciscan Physician Network- Indiana Heart Physicians
        • Contact:
          • Ryan P Daly, MD
      • Indianapolis, Indiana, États-Unis, 46202
        • Recrutement
        • Indiana Medical Research Institute
        • Contact:
          • Arshad P. Malik
    • Iowa
      • West Des Moines, Iowa, États-Unis, 50266
        • Recrutement
        • MercyOne Iowa Heart Center
        • Contact:
          • Enrico L. Martin, MD
    • Kentucky
      • Edgewood, Kentucky, États-Unis, 41017
        • Recrutement
        • St Elizabeth Health Care - CRI
        • Contact:
          • Erica Pivato, MD
      • Louisville, Kentucky, États-Unis, 40202
        • Recrutement
        • UofL Health
        • Contact:
          • Shahab Ghafghazi, MD
    • Louisiana
      • New Orleans, Louisiana, États-Unis, 70127
        • Recrutement
        • Ascension DePaul Services Research Center
        • Contact:
          • Kristen Thomas, MD
    • Maryland
      • Bowie, Maryland, États-Unis, 20715
        • Recrutement
        • Flourish Bowie dba Flourish Research
        • Contact:
          • Sara Collins, MD
      • Columbia, Maryland, États-Unis, 21045
        • Recrutement
        • KUR Research at CMP
        • Contact:
          • William Saway, MD
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02115
        • Recrutement
        • Brigham and Women's Hospital
        • Contact:
          • Ron Blankstein, MD
      • Boston, Massachusetts, États-Unis, 02114
        • Recrutement
        • Massachusetts General Hospital
        • Contact:
          • Pradeep Natarajan, MD
    • Michigan
      • Detroit, Michigan, États-Unis, 48202
        • Recrutement
        • Henry Ford Hospital
        • Contact:
          • Cori E Russell, MD
      • Ypsilanti, Michigan, États-Unis, 48917
        • Recrutement
        • Trinity Health Michigan Heart
        • Contact:
          • Ahmad Mizyed, MD
    • Minnesota
      • Minneapolis, Minnesota, États-Unis, 55407
        • Recrutement
        • Minneapolis Heart Institute Foundation
        • Contact:
          • Michael D. Miedema, MD
    • Missouri
      • St Louis, Missouri, États-Unis, 63110
        • Recrutement
        • Washington University School of Medicine
        • Contact:
          • Farhan M. Katchi, MD
      • St Louis, Missouri, États-Unis, 63136
        • Recrutement
        • Saint Louis Heart and Vascular
        • Contact:
          • Gil Vardi, MD
    • Montana
      • Kalispell, Montana, États-Unis, 59901
        • Recrutement
        • Boeson Research Kalispell
        • Contact:
          • Justin Buls, MD
      • Missoula, Montana, États-Unis, 59804
        • Recrutement
        • Boeson Research Fort Missoula
        • Contact:
          • Audrey Remmers, MD
    • Nebraska
      • Lincoln, Nebraska, États-Unis, 68506
        • Recrutement
        • Bryan Heart
        • Contact:
          • Chad E. Travers, MD
    • Nevada
      • Las Vegas, Nevada, États-Unis, 89128
        • Recrutement
        • Vector Clinical Trials
        • Contact:
          • Bharat R. Mocherla, MD
      • Las Vegas, Nevada, États-Unis, 89102
        • Recrutement
        • Southwest Medical Associates- Optum Nevada
        • Contact:
          • Tatiana O. Tsvetkova, MD
    • New Jersey
      • Flemington, New Jersey, États-Unis, 08822
        • Recrutement
        • Advanced Heart and Vascular Institute of Hunterdon
        • Contact:
          • Andrey Espinoza, MD
      • Marlton, New Jersey, États-Unis, 08053
        • Recrutement
        • Virtua Health, Inc.
        • Contact:
          • Mark T. Finch, MD
      • New Brunswick, New Jersey, États-Unis, 08901
        • Recrutement
        • Rutgers State University
        • Contact:
          • Sabahat Bokhari, MD
      • Paramus, New Jersey, États-Unis, 07652
        • Recrutement
        • The Valley Hospital
        • Contact:
          • Himanshu Gupta, MD
      • Teaneck, New Jersey, États-Unis, 07666
        • Recrutement
        • Holy Name Medical Center
        • Contact:
          • Jaffar Raza, MD
    • New York
      • Brooklyn, New York, États-Unis, 11221
        • Recrutement
        • Clindove Research
        • Contact:
          • Nelly Cohen, MD
      • Brooklyn, New York, États-Unis, 11226
        • Recrutement
        • Swift Clinical Research
        • Contact:
          • Manoj Dalmia, MD
      • Jackson Heights, New York, États-Unis, 11372
        • Recrutement
        • Rasaj Research
        • Contact:
          • Ammara Mushtaq, MD
      • Lake Success, New York, États-Unis, 11042
        • Recrutement
        • Optum- Long Island NY
        • Contact:
          • Steven Goldberg, MD
      • Mount Kisco, New York, États-Unis, 10549
        • Recrutement
        • Northwell Health Northern Westchester Hospital
        • Contact:
          • Margaret Andersen, MD
      • New York, New York, États-Unis, 10019
        • Recrutement
        • Mount Sinai West
        • Contact:
          • Waqas A Malick, MD
      • New York, New York, États-Unis, 10029
        • Recrutement
        • Mount Sinai
        • Contact:
          • Solomon Bienstock, MD
    • North Carolina
      • Chapel Hill, North Carolina, États-Unis, 27599
        • Recrutement
        • University of North Carolina at Chapel Hill
        • Contact:
          • Matthew Cavender, MD
      • Durham, North Carolina, États-Unis, 27701
        • Recrutement
        • Duke University Hospital
        • Contact:
          • William Yancy, MD
      • Durham, North Carolina, États-Unis, 27705
        • Recrutement
        • Durham Veterans Affairs Medical Center (Durham VAMC)
        • Contact:
          • Hayden Bosworth, MD
      • Fayetteville, North Carolina, États-Unis, 28304
        • Recrutement
        • Cape Fear Valley Health System (Javara Inc.)
        • Contact:
          • Nafisa Saleem, MD
      • Morehead City, North Carolina, États-Unis, 28557
        • Actif, ne recrute pas
        • West Clinical Research
      • Winston-Salem, North Carolina, États-Unis, 27157
        • Recrutement
        • Wake Forest University Health Sciences
        • Contact:
          • Michael Shapiro, MD
    • North Dakota
      • Fargo, North Dakota, États-Unis, 58102
        • Recrutement
        • Sanford Health
        • Contact:
          • David J. Clardy, MD
    • Ohio
      • Akron, Ohio, États-Unis, 44304
        • Recrutement
        • Summa Health
        • Contact:
          • Wissam Alajaji, MD
    • Oklahoma
      • Oklahoma City, Oklahoma, États-Unis, 73109
        • Recrutement
        • Medical Research International, LLC
        • Contact:
          • Joseph Grillo, MD
      • Oklahoma City, Oklahoma, États-Unis, 73007
        • Recrutement
        • Hightower Clinical
        • Contact:
          • Faisal Latif, MD
      • Tulsa, Oklahoma, États-Unis, 74104
        • Recrutement
        • Ascension St. John - Jane Phillips Medical Center
        • Contact:
          • Michael Megaly, MD
    • Pennsylvania
      • Camp Hill, Pennsylvania, États-Unis, 17011
        • Recrutement
        • Capital Area Research
        • Contact:
          • Venkatesh Nadar, MD
    • South Carolina
      • Charleston, South Carolina, États-Unis, 29425
        • Recrutement
        • Medical University of South Carolina
        • Contact:
          • Marc-Andre Cornier, MD
    • Tennessee
      • Cleveland, Tennessee, États-Unis, 37312
        • Recrutement
        • Community DPC
        • Contact:
          • Carlton Volberg, MD
      • Knoxville, Tennessee, États-Unis, 37920
        • Recrutement
        • University of Tennessee Medical Center
        • Contact:
          • Kashif A. Shaikh, MD
      • Nashville, Tennessee, États-Unis, 37202
        • Recrutement
        • TriStar Centennial Medical Center (HCA Health Care)
        • Contact:
          • David Huneycutt, MD
    • Texas
      • Abilene, Texas, États-Unis, 79601
        • Recrutement
        • Hendrick Health
        • Contact:
          • Ren Zhang, MD
      • Beaumont, Texas, États-Unis, 77702
        • Recrutement
        • Gadolin Research
        • Contact:
          • John T Fowler, MD
      • Greenville, Texas, États-Unis, 75402
        • Recrutement
        • CardioVoyage, LLC
        • Contact:
          • Marc Demyun, MD
      • Houston, Texas, États-Unis, 77025
        • Recrutement
        • Kelsey Research Foundation
        • Contact:
          • Rohan R Wagle, MD
      • Houston, Texas, États-Unis, 77004
        • Recrutement
        • Helium Research Group
        • Contact:
          • Ijeoma A. Ekeruo
      • Houston, Texas, États-Unis, 77070
        • Recrutement
        • Gulf Coast Clinical Research, LLC
        • Contact:
          • Anjani Pandya, MD
      • Houston, Texas, États-Unis, 77030
        • Recrutement
        • The Methodist Hospital, DeBakey Cardiology Associates
        • Contact:
          • Sadeer Al-Kindi, MD
      • Laredo, Texas, États-Unis, 78041
        • Recrutement
        • Aeres Clinical Research
        • Contact:
          • Amando Garza, MD
      • Lewisville, Texas, États-Unis, 75057
        • Recrutement
        • DC Clinical Research
        • Contact:
          • Moiz M. Shafiq, MD
      • McKinney, Texas, États-Unis, 75069
        • Recrutement
        • North Dallas Research Associates - Kerlo Network
        • Contact:
          • Muhammad Akram Khan, MD
      • Mesquite, Texas, États-Unis, 75149
        • Recrutement
        • SMS Clinical Research
        • Contact:
          • Salma Saiger, MD
      • San Marcos, Texas, États-Unis, 78666
        • Recrutement
        • Privia Medical Group Gulf Coast, PLLC ( Javara Inc.)
        • Contact:
          • Alan Lee, MD
      • Stephenville, Texas, États-Unis, 76401
        • Recrutement
        • Privia Medical Group- North Texas
        • Contact:
          • Benjamin Marcum, MD
    • Utah
      • West Valley City, Utah, États-Unis, 84120
        • Pas encore de recrutement
        • Kalo Clinical Research
        • Contact:
          • William J. Walsh, MD
    • Virginia
      • Richmond, Virginia, États-Unis, 23225
        • Recrutement
        • Chippenham Johnston Willis Medical Center
        • Contact:
          • Michael Arcarese, MD
    • Washington
      • Everett, Washington, États-Unis, 98201
        • Recrutement
        • Providence Regional Medical Center Everett
        • Contact:
          • Xiaojing Jennie Shen, MD
      • Seattle, Washington, États-Unis, 98195
        • Recrutement
        • University of Washington
        • Contact:
          • Kelley Branch, MD
    • West Virginia
      • Charleston, West Virginia, États-Unis, 25304
        • Recrutement
        • Charleston Area Medical Center
        • Contact:
          • Sarah Rinehart, MD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

55 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Provided electronic or written informed consent

  2. Men > 55, women > 65 years of age

  3. Type 2 diabetes mellitus requiring pharmacologic therapy or with their most recent A1c 6.5%. Patients with prediabetes (most recent HbA1c 5.7 to 6.4% and/or fasting glucose 100-125 mg/dL [5.6-6.9 mmol/L]) and/or metabolic syndrome can be enrolled through 12 October 2026 and proceed with randomization; however, no additional participants may enroll with these criteria after this date. Metabolic syndrome is defined as > 3 of the following criteria (International Diabetes Federation 2006):

    • Body mass index ≥ 27 kg/m2 or abnormal waist circumference defined as ≥ 80 cm (31.5 inches) for women, ≥ 94 cm (37 inches) for men; for South and East Asian men (e.g., Asian Indian, Chinese, Japanese) ≥ 90 cm (35.4 inches)
    • Fasting triglycerides ≥ 150 mg/dL (1.7 mmol/L) or treated hypertriglyceridemia
    • HDL-cholesterol (HDL-C) < 40 mg/dL (1.03 mmol/L) in men, <50 mg/dL (1.29 mmol/L) in women or treatment for this lipid abnormality
    • Systolic blood pressure (BP) ≥ 130 and/or diastolic BP≥ 85 mm Hg and/or treated hypertension
    • Fasting blood glucose ≥ 100 mg/dL (5.6 mmol/L) or HbA1c ≥ 5.7%
  4. Have a device (e.g., smartphone, tablet, computer) for communication with the central cardiologist-led team managing drug treatment for the personalized care group

Exclusion Criteria:

  1. Any one of the following:

    1. A history of acute myocardial infarction (heart attack), stroke, or non-traumatic leg/foot/toe amputation
    2. A history of an arterial revascularization procedure for coronary, peripheral, and/or carotid atherosclerotic disease (i.e. coronary stent or bypass, carotid stent)
    3. Symptoms suspicious of coronary artery disease, stroke or peripheral artery disease confirmed by a diagnostic test within the last 12 months (i.e. nuclear stress test, invasive angiogram, brain MRI/CT
    4. Asymptomatic ASCVD including treatment with therapies (e.g. antiplatelets, lipid lowering) intended to reduce CV risk due to the imaging evidence of atherosclerosis and/or management to goals consistent with secondary prevention guidelines (e.g. LDL-C < 70 mg/dL)
  2. Planned arterial revascularization

  3. Inability to complete screening CCTA or any condition that would increase the risk associated with CCTA or increase likelihood of uninterpretable scan including:

    1. eGFR < 60 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) or Modification of Diet in Renal Disease (MDRD) equation (www.kidney.org/professionals/kdoqi/gfr_calculator)
    2. Allergy to iodinated contrast or history of contrast-induced nephropathy (including adverse reaction to contrast at screening CCTA) or screening laboratory values consistent with untreated hyperthyroidism. Participants with elevated thyroid-stimulating hormone (TSH) may be enrolled but should be referred to their physician for evaluation for treatment.
    3. Thyroid cancer in the previous five (5) years or planned radioactive iodine treatment
    4. Weight > 300 lbs. (136 kg) or above manufacturer-recommended limit for scanner and table at the site
    5. Inability to hold breath for > 10 seconds
    6. Active arrhythmia (atrial fibrillation, atrial flutter, frequent premature atrial, or ventricular contractions) with poorly controlled rate (i.e., > 80 beats per minute at screening or prior to CCTA)
    7. Contraindication to dosing with beta blocker or nitroglycerin on day of screening CCTA
    8. Any other factor that, in the opinion of the investigator, would increase participant risk or increase the chance of an uninterpretable CCTA
  4. Unsuitable as a trial participant in the opinion of the investigator for reasons including significant left main stenosis (e.g. ≥ 70%; site will be notified by Cleerly), other health condition with life expectancy < 3 years or being at risk of poor compliance with study procedures (e.g., active substance abuse or untreated mental illness that, in the opinion of the investigator, is likely to adversely affect adherence or retention)

  5. Unwilling or unable to receive specialty care per the trial protocol

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Aucune intervention: Risk Factor-Based Care

The risk factor-based care group will be managed by their usual care providers, with an initial pre-randomization assessment of current treatment by a centralized cardiology team to optimize care relative to primary prevention guidelines. During the trial, the centralized cardiology team will monitor the provision of medications prescribed and lab values relative to guidelines, and provide feedback and education to site investigators to support optimization. CCTA results will be centrally archived and will remain blinded to the usual care provider until the end of the study.

Expérimental: Cleerly Stage-Based Care

The Cleerly Stage-Based Care group will receive personalized care centrally managed by a remote cardiologist-led team. They will also receive an initial pre-randomization assessment of current treatment by a centralized cardiology team to optimize care relative to primary prevention guidelines. Cleerly CAD Staging System results will be discussed with participants and serve as the basis for standardized algorithm-supported pharmacotherapy & education, which will be intensified if plaque burden has progressed at 24 months.

The Cleerly CAD Staging System is software that utilizes a proprietary algorithm to identify CAD, stage the severity of CAD when present, and generate a prognostic risk score to inform treatment decisions that support CV disease prevention.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
The primary objective is to compare Cleerly stage-based care with risk factor-based care on the risk of CV events.
Délai: Through study completion- an average of 3.5 years

The primary endpoint is total (first and subsequent) events for the composite endpoint of CV death, myocardial infarction (MI), ischemic stroke, acute limb ischemia, clinically driven arterial revascularization, and hospitalization or urgent visit for heart failure.

Through study completion- an average of 3.5 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Délai: Through study completion- an average of 3.5 years

The secondary endpoints are time from randomization to first occurence of an event in the primary efficacy endpoint.

Through study completion- an average of 3.5 years
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Délai: Through study completion- an average of 3.5 years

The secondary endpoints are total occurences after randomization of the primary efficacy endpoing, kidney failure, sustained estimated glomerular filtration rate (eGFR) decrease >40% from baseline, and death from renal causes.

Through study completion- an average of 3.5 years
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Délai: Through study completion- an average of 3.5 years

The secondary endpoints are first and total occurrences after randomization of coronary death, MI, and urgent coronary revascularization.

Through study completion- an average of 3.5 years
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Délai: Through study completion- an average of 3.5 years

The secondary endpoints are time from randomization to first occurrence of MI or ischemic stroke.

Through study completion- an average of 3.5 years
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Délai: Through study completion- an average of 3.5 years

The secondary endpoints are time from randomization to all-cause death.

Through study completion- an average of 3.5 years

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
The safety objective is to assess harm with the 2 prevention strategies
Délai: Through study completion- an average of 3.5 years

The safety endpoints are Adverse events (AE) leading to discontinuation of study-recommended medication (DAE), serious AE (SAE), adverse device effect (ADE).

Through study completion- an average of 3.5 years
The safety objective is to assess harm with the 2 prevention strategies
Délai: Through study completion- an average of 3.5 years

The safety endpoints are 20-item Short Form survey (SF-20).

Through study completion- an average of 3.5 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Les enquêteurs

  • Chaise d'étude: Deepak Bhatt, MD, MPH, Mt. Sinai Heart
  • Chaise d'étude: David J. Maron, MD, FASPC, Stanford University

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

6 mars 2024

Achèvement primaire (Estimé)

5 mars 2029

Achèvement de l'étude (Estimé)

5 mars 2029

Dates d'inscription aux études

Première soumission

2 octobre 2023

Première soumission répondant aux critères de contrôle qualité

31 octobre 2023

Première publication (Réel)

1 novembre 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

18 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 202302CPC

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Oui

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .